Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Fajac

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 4, 2017
A multiple reader scoring system for Nasal Potential Difference parametersGeorge M Solomon, Bo Liu, Isabelle Sermet-Gaudelus, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 20, 2008
In vivo gene delivery in the mouse lung with lactosylated polyethylenimine, questioning the relevance of in vitro experimentsStéphanie Grosse, Guiti Thévenot, Yolande Aron, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 9, 2019
Insights into the variability of nasal potential difference, a biomarker of CFTR activitySpyridoula Kyrilli, Theophraste Henry, Michael Wilschanski, et al.
ERJ Open Research|December 14, 2020
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF<sup>TM</sup> 1Christopher H Goss, Raksha Jain, Wolfgang Seibold, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2010
Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasisThierry Bienvenu, Isabelle Sermet-Gaudelus, Pierre-Regis Burgel, et al.
Pulmonary Therapy|June 8, 2021
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource UtilizationDominique Hubert, Christophe Marguet, Jacques Benichou, et al.
Pulmonary Therapy|July 14, 2021
Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource UtilizationDominique Hubert, Christophe Marguet, Jacques Benichou, et al.
The Journal of Gene Medicine|January 8, 2003
Uptake of plasmid/glycosylated polymer complexes and gene transfer efficiency in differentiated airway epithelial cellsIsabelle Fajac, Guiti Thévenot, Laurent Bédouet, et al.
The European Respiratory Journal|August 13, 2021
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II studyChristopher H Goss, Isabelle Fajac, Raksha Jain, et al.
American Journal of Respiratory and Critical Care Medicine|March 8, 2021
Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19Thông Hua-Huy, Christine Lorut, Frédérique Aubourg, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 4, 2017
A multiple reader scoring system for Nasal Potential Difference parametersGeorge M Solomon, Bo Liu, Isabelle Sermet-Gaudelus, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 20, 2008
In vivo gene delivery in the mouse lung with lactosylated polyethylenimine, questioning the relevance of in vitro experimentsStéphanie Grosse, Guiti Thévenot, Yolande Aron, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 9, 2019
Insights into the variability of nasal potential difference, a biomarker of CFTR activitySpyridoula Kyrilli, Theophraste Henry, Michael Wilschanski, et al.
ERJ Open Research|December 14, 2020
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF<sup>TM</sup> 1Christopher H Goss, Raksha Jain, Wolfgang Seibold, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2010
Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasisThierry Bienvenu, Isabelle Sermet-Gaudelus, Pierre-Regis Burgel, et al.
Pulmonary Therapy|June 8, 2021
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource UtilizationDominique Hubert, Christophe Marguet, Jacques Benichou, et al.
Pulmonary Therapy|July 14, 2021
Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource UtilizationDominique Hubert, Christophe Marguet, Jacques Benichou, et al.
The Journal of Gene Medicine|January 8, 2003
Uptake of plasmid/glycosylated polymer complexes and gene transfer efficiency in differentiated airway epithelial cellsIsabelle Fajac, Guiti Thévenot, Laurent Bédouet, et al.
The European Respiratory Journal|August 13, 2021
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II studyChristopher H Goss, Isabelle Fajac, Raksha Jain, et al.
American Journal of Respiratory and Critical Care Medicine|March 8, 2021
Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19Thông Hua-Huy, Christine Lorut, Frédérique Aubourg, et al.
Pageof 8